LAB
Standard BioTools, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.64
+2.27%Year over year
Reported trailing growth
- Revenue
- -36.7%
- EBITDA
- -13.8%
- EBIT
- +28.7%
- EPS
- +28.0%
- Free cash flow
- +21.7%
- Operating cash flow
- +13.5%
Forward estimates
Based on analyst estimates
- Revenue
- -2.8%
- EBITDA
- +38.5%
- EPS
- +30.6%
Three-year CAGR
- Revenue
- -4.5%
- EBITDA
- +27.5%
- EBIT
- +46.8%
- Net income
- +46.1%
- EPS
- +61.5%
- Free cash flow
- +45.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026